The protective effect of bone marrow-derived mesenchymal stem cells in liver ischemia/reperfusion injury via down-regulation of miR-370.
Apoptosis
BAX
Bcl2
Ischemia reperfusion injury
Mesenchymal stem cells
microRNA 370
Journal
Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
25
6
2019
pubmed:
25
6
2019
medline:
25
6
2019
Statut:
ppublish
Résumé
Liver transplantation is the most important therapy for end-stage liver disease and ischemia reperfusion (I/R) injury is indeed a risk factor for hepatic failure after grafting. The role of miRNAs in I/R is not completely understood. The aim of this study was to investigate the potential protective role of the mesenchymal stem cells (MSCs) and ischemic preconditioning on miR-370 expression and tissue injury in hepatic I/R injury. In this study, 24 BALB/c mice were divided into 4 groups, including sham, I/R, I/R mouse that received MSCs (I/R+MSC) and ischemia preconditioning (IPC) The expression levels of hepatic miR-370, Bcl2 and BAX in male BALB/c mice in different groups including hepatic I/R, hepatic I/R received MSCs, and hepatic I/R with IPC were assessed by quantitative real-time PCR. The effect of miR-370 on hepatic I/R was investigated by serum liver enzyme analysis and histological examination. The expression of miR-370 was significantly up-regulated in the mice subjected to hepatic I/R injury as compared with the sham operated mice. Injection of MSCs led to the down-regulation of the serum liver enzymes, expression of miR-370 and BAX, up-regulation of Bcl2 as well as the improvement of hepatic histological damage. IPC led to similar results, but the difference was not significant. Our data suggest that miR-370 affected the Blc2/BAX pathway in hepatic I/R injury, and down- regulation of miR-370 by BM-MSCs efficiently attenuated the liver damage.
Identifiants
pubmed: 31231497
doi: 10.22038/ijbms.2019.32670.7812
pmc: PMC6570750
doi:
Types de publication
Journal Article
Langues
eng
Pagination
683-689Déclaration de conflit d'intérêts
The authors declare that they are no conflicts of interest.
Références
Science. 2004 Jan 2;303(5654):83-6
pubmed: 14657504
Transplant Proc. 2005 Jan-Feb;37(1):439-41
pubmed: 15808669
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Proteomics. 2006 Jun;6(11):3455-65
pubmed: 16622838
Transplantation. 1991 Dec;52(6):979-83
pubmed: 1750084
Arch Biochem Biophys. 2009 Apr 15;484(2):232-7
pubmed: 18940177
J Gastrointest Surg. 2009 Nov;13(11):2074-83
pubmed: 19404711
J Lipid Res. 2010 Jun;51(6):1513-23
pubmed: 20124555
J Bone Miner Res. 2010 Jul;25(7):1604-15
pubmed: 20200974
Liver Transpl. 2010 Sep;16(9):1016-32
pubmed: 20818739
Nat Med. 2011 Nov 07;17(11):1391-401
pubmed: 22064429
J Surg Res. 2012 Dec;178(2):935-48
pubmed: 22658855
PLoS One. 2012;7(9):e45825
pubmed: 23029264
Biomed Pharmacother. 2013 Jul;67(6):521-6
pubmed: 23721824
J Hepatol. 2013 Nov;59(5):1094-106
pubmed: 23811302
Biomed Pharmacother. 2014 Mar;68(2):149-54
pubmed: 24055400
Liver Int. 2015 Apr;35(4):1124-32
pubmed: 24351048
Nat Commun. 2014;5:3315
pubmed: 24525530
PLoS One. 2014 Mar 25;9(3):e93304
pubmed: 24667691
PLoS One. 2014 May 05;9(5):e96836
pubmed: 24797571
Arthritis Rheumatol. 2014 Dec;66(12):3349-58
pubmed: 25186470
J Transl Med. 2014 Oct 11;12:260
pubmed: 25304688
J Immunol Res. 2015;2015:602597
pubmed: 26258151
J Toxicol Sci. 2015;40(5):637-45
pubmed: 26354380
Nitric Oxide. 2016 Aug 31;58:10-9
pubmed: 27246638
Eur Rev Med Pharmacol Sci. 2016 May;20(10):2011-9
pubmed: 27249599
Transplant Proc. 2016 May;48(4):1247-50
pubmed: 27320597
Cytotherapy. 2016 Dec;18(12):1548-1559
pubmed: 27592404
Biomed Rep. 2016 Sep;5(3):332-336
pubmed: 27602213
Am J Transl Res. 2016 Oct 15;8(10):4289-4299
pubmed: 27830012
Stem Cells Int. 2016;2016:1240301
pubmed: 27843457